Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | MIF | P14174 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.40 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KLK7 | P49862 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24593481 | 1.00 | L3MBTL1 (0.41) | L3MBTL1MIFMEN1KMT2AHPGD | |
| SCHEMBL21664445 | 0.89 | NAAA (0.49) | HPGDNAAAPSMB8 | |
| SCHEMBL20801422 | 0.88 | NAAA (0.51) | MEN1KMT2AHPGDNAAATDP1 | |
| SCHEMBL22181049 | 0.88 | NAAA (0.51) | MEN1KMT2AHPGDNAAATDP1 | |
| SCHEMBL24860007 | 0.88 | NAAA (0.51) | MEN1KMT2AHPGDNAAATDP1 | |
| SCHEMBL18779827 | 0.88 | NAAA (0.51) | MEN1KMT2AHPGDNAAATDP1 | |
| SCHEMBL24622843 | 0.88 | NAAA (0.47) | MEN1KMT2AHPGDNAAAPSMB8 | |
| SCHEMBL24860099 | 0.84 | NAAA (0.40) | NAAAPSMB8SMN1; SMN2 | |
| SCHEMBL20801484 | 0.84 | NAAA (0.40) | NAAAPSMB8SMN1; SMN2 | |
| SCHEMBL18610478 | 0.83 | HPGD (0.37) | L3MBTL1KMT2AHPGDALDH1A1PSMB8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11667621-B2 | Antiestrogen compounds | STEVENS INSTITUTE OF TECHNOLOGY (US) | 2023-06-06 | — | — | US | disclosed |
| US-20210130320-A1 | ANTIESTROGEN COMPOUNDS | STEVENS INSTITUTE OF TECHNOLOGY (US) | 2021-05-06 | — | — | US | disclosed |
| EP-0449884-A4 | DERIVATIVES OF TETRAPEPTIDES AS CCK AGONISTS | — | 1991-10-30 | — | — | EP | disclosed |
| EP-0449884-A1 | DERIVATIVES OF TETRAPEPTIDES AS CCK AGONISTS | ABBOTT LABORATORIES (US) | 1991-10-09 | — | — | EP | disclosed |
| WO-1990006937-A1 | DERIVATIVES OF TETRAPEPTIDES AS CCK AGONISTS | ABBOTT LABORATORIES (US) | 1990-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11667621-B2 | Antiestrogen compounds | ESR1, ESR2, ESRRG | L3MBTL1 1747/4885MIF 2288/4885MEN1 2747/4885 |
| US-20210130320-A1 | ANTIESTROGEN COMPOUNDS | ESR1, ESR2, ESRRG | L3MBTL1 1747/4885MIF 2288/4885MEN1 2747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.